The FDA has approved delafloxacin (Baxdela™, Melinta Therapeutics), a new antibacterial drug to treat acute bacterial skin and skin structure infections.
Patients with a simple abscess who received TMP-SMX along with incision and drainage had improved short-term outcomes compared to those who just received incision and drainage.
The risk of a cardiovascular event may be increased with herpes zoster.
Results from atrial of clindamycin in cellulitis cast doubt on hospital guidelines.
There have been an increase in number of emergency department visits and costs for HZ-related ER visits.
Common rheumatoid arthritis drugs methotrexate and biologics may increase risk for herpes zoster.
Frequent recurrence of erysipelas has been a major challenge to treatment. Investigators looked at adjustments to the dosing schedule to improve efficacy of an existing therapy.
Adding trimethoprim-sulfamethoxazole to cephalexin treatment for cellulitis does not benefit outcomes compared to cephalexin alone.
Use of standard Helicobacter pylori eradication therapy is associated with improvement in rosacea.
Researchers find use of antibiotics ineffective for mild clinically infected eczema in children.
Phase 3 study looked at the safety, tolerability, efficacy, and immunogenicity of inactivated VZV Vaccine in recipients of auto-HSCT.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Infections Complicate Biologic Use in Autoimmune Inflammatory Disorders
- Some Antibiotics May Reduce Biofilm in Urinary Tract Infections
- Tuberculosis Vaccine May Reverse Type 1 Diabetes
- Sepsis-Related Mortality Decreased With Rapid Implementation of Protocol
- No Benefits Seen for Adjunctive Clindamycin in Cellulitis
- Increased Incidence of Chlamydia Due to Changes in Cancer Screening Guidelines
- Serratia marcescens Outbreak After Drug Tampering in US Hospital
- Meningococcal Disease Risk Linked to Eculizumab Despite Vaccination
- Medicaid Enrollees Largely Satisfied With Their Health Care
- Ebola Vaccine Long-Term Safety and Antibody Response